Independent intelligence for the laboratory world

Caris Expands Liquid Biopsy With Integrated DNA and RNA Analysis

Caris Life Sciences expands its Assure liquid-biopsy platform with whole-exome, transcriptome, and whole-blood analysis.

Press release summary

Caris Life Sciences has expanded its Caris Assure liquid-biopsy platform by combining whole-exome sequencing, whole-transcriptome sequencing, and whole-blood analysis in a single assay.

The whole-blood component is intended to distinguish clonal hematopoiesis of indeterminate potential, or CHIP, from tumor-derived findings. Caris said the enhanced test covers more than 23,000 genes, reaches therapy-focused sequencing depth of up to 40,000 times, and produces approximately 600 million RNA reads. The company also added validated human leukocyte antigen reporting, expanded pharmacogenomic information, improved fusion detection, and revised clinical reports.

Caris reports a median turnaround time of about seven days. The announcement did not provide comparative clinical-validation data or detailed performance characteristics for each added component.

Why it matters for laboratories

Integrating DNA, RNA, and matched whole-blood analysis may reduce the need for separate molecular workflows while helping laboratories identify blood-cell variants that could confound tumor interpretation. The broader data set also increases demands on bioinformatics, quality control, variant review, and report governance. Laboratories and oncology programs should evaluate analytical validation, specimen requirements, coverage limitations, and evidence supporting treatment associations before adopting the expanded platform.

Original source: Caris Life Sciences press release, Sept. 29, 2026.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *